Lorazepam-d4 (CRM) is intended for use as an internal standard for the quantification of lorazepam .2,3 Formulations containing lorazepam have been used in the treatment of anxiety. Lorazepam-d4 is regulated as a Schedule IV compound in the United States. Lorazepam-d4 (CRM) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.
References:
[1].Miller, L.G., Greenblatt, D.J., Barnhill, J.G., et al.Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased γ-aminobutyric acidA receptor functionJ. Pharmacol. Exp. Ther.246(1)170-176(1988).
[2].Baldwin, D., Woods, R., Lawson, R., et al.Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysisBMJ342d1199(2011).
[3].Moosmann, B., Bisel, P., and Auwärter, V.Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokineticsDrug Test Anal.6(7-8)757-763(2014).